FY2024 EPS Estimates for Amedisys, Inc. (NASDAQ:AMED) Raised by Analyst

Amedisys, Inc. (NASDAQ:AMED) – William Blair increased their FY2024 EPS estimates for Amedisys in a research note issued on Thursday, April 25th. William Blair analyst M. Larew now forecasts that the health services provider will post earnings per share of $4.54 for the year, up from their prior estimate of $4.37. The consensus estimate for Amedisys’ current full-year earnings is $4.58 per share.

Several other equities research analysts have also recently weighed in on AMED. Royal Bank of Canada boosted their price objective on Amedisys from $97.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 25th. Cantor Fitzgerald reissued a “neutral” rating and set a $101.00 target price on shares of Amedisys in a research report on Thursday, April 25th. Raymond James restated a “market perform” rating on shares of Amedisys in a report on Tuesday, March 26th. Finally, StockNews.com lowered shares of Amedisys from a “buy” rating to a “hold” rating in a research note on Friday, April 26th. Eight equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Amedisys currently has an average rating of “Hold” and a consensus target price of $97.50.

Amedisys Stock Up 0.2 %

Shares of NASDAQ AMED opened at $92.05 on Monday. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. Amedisys has a 12-month low of $73.10 and a 12-month high of $96.44. The firm’s 50-day moving average price is $92.51 and its 200-day moving average price is $93.35. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of -143.83, a P/E/G ratio of 3.41 and a beta of 0.86.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, April 24th. The health services provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Amedisys had a negative net margin of 0.91% and a positive return on equity of 12.85%. The business had revenue of $571.41 million during the quarter, compared to analyst estimates of $565.38 million. During the same quarter last year, the business earned $1.00 earnings per share. Amedisys’s quarterly revenue was up 2.7% compared to the same quarter last year.

Institutional Investors Weigh In On Amedisys

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in Amedisys by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,241,160 shares of the health services provider’s stock valued at $302,724,000 after acquiring an additional 12,137 shares during the period. Alpine Associates Management Inc. lifted its position in shares of Amedisys by 23.0% during the fourth quarter. Alpine Associates Management Inc. now owns 1,271,097 shares of the health services provider’s stock worth $120,830,000 after purchasing an additional 237,600 shares during the last quarter. Pentwater Capital Management LP boosted its stake in shares of Amedisys by 239.5% during the third quarter. Pentwater Capital Management LP now owns 1,144,000 shares of the health services provider’s stock valued at $106,850,000 after purchasing an additional 807,000 shares during the period. Westchester Capital Management LLC grew its holdings in shares of Amedisys by 3.4% in the fourth quarter. Westchester Capital Management LLC now owns 879,402 shares of the health services provider’s stock worth $83,596,000 after purchasing an additional 29,016 shares during the last quarter. Finally, Park West Asset Management LLC grew its holdings in shares of Amedisys by 8.0% in the fourth quarter. Park West Asset Management LLC now owns 812,069 shares of the health services provider’s stock worth $77,195,000 after purchasing an additional 60,350 shares during the last quarter. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.